This post was originally published on this site
(Reuters) – Giving COVID-19 vaccines from either AstraZeneca-Oxford, Pfizer-BioNTech or Johnson & Johnson (NYSE:JNJ) as a booster after two doses of the COVID-19 inactivated-virus vaccine from Sinovac, leads to significantly higher antibodies, a study has found.
The best response was seen when an RNA vaccine was given as a booster after the standard schedule of Sinovac’s CoronaVac, researchers from Oxford University said on Monday, adding that the responses were seen against the Delta and Omicron coronavirus variants too.
